Pharmaceuticals News

Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering  Company remains on track to begin patient dosing this year and report initial safety...

Management call today at 3.30 pm CEST Newron received the anticipated FDA written communication on clinical hold at U.S. study centers and is reviewing feedback and preparing its response ENIGMA-TRS...

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,...

First-Quarter Results Reinforce Tilray’s Progress Converting Global Scale, Disciplined Execution and Category Leadership into Higher Revenue, Expanded Gross Profit and Continued Momentum Record...

Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an...

Forventningerne til omsætning og EBITDA-margin er opjusteret som følge af et stærkere salg i Travel Health end forventet. KØBENHAVN, Danmark, 8. oktober 2026 – Bavarian Nordic A/S (OMX: BAVA)...

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...

October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY...

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with...